Renal & Urinary System

{"ops":[{"insert":"Recombinant Human Erythropoietin"},{"insert":"\n","attributes":{"header":1}},{"insert":"Recombinant human erythropoietin (RHuEPO), or simply recombinant erythropoietin (rhEPO), is an exogenous erythropoietin produced by recombinant DNA technology.\r\n\r\nThe introduction of RHuEPO has revolutionised the treatment of patients with anemia of chronic kidney disease (CKD), who as a rule, universally demonstrate subnormal endogenous erythropoietin production.\r\n\r\nClinical studies have shown that RHuEPO therapy corrects anemia of chronic renal failure, reduces the need for blood transfusions and improves the quality of life. \r\n\r\nFurthermore, it optimises the patient\u0027s hemodynamic status, thus minimising the risk of progression to left ventricular hypertrophy, with its associated mortality. \r\n\r\nA potential downside is the risk of an incre"}]}

Want to continue playing?

Open your Clinical Odyssey account today.

Enjoy unlimited access to 600+ simulations.
Safely improve your skills, anytime and anywhere.
Get answers to your follow-up questions from practicing physicians.